Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

34 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pharmacokinetics and pharmacodynamics of finerenone in patients with chronic kidney disease and type 2 diabetes: Insights based on FIGARO-DKD and FIDELIO-DKD.
Eissing T, Goulooze SC, van den Berg P, van Noort M, Ruppert M, Snelder N, Garmann D, Lippert J, Heinig R, Brinker M, Heerspink HJL. Eissing T, et al. Among authors: garmann d. Diabetes Obes Metab. 2024 Mar;26(3):924-936. doi: 10.1111/dom.15387. Epub 2023 Nov 30. Diabetes Obes Metab. 2024. PMID: 38037539 Clinical Trial.
Reactivity of novel albumin-binding platinum complexes.
Garmann D, Warnecke A, Kratz F, Jaehde U. Garmann D, et al. Int J Clin Pharmacol Ther. 2004 Nov;42(11):646-7. doi: 10.5414/cpp42646. Int J Clin Pharmacol Ther. 2004. PMID: 15598033 No abstract available.
Population Pharmacokinetic and Exposure-Response Analysis of Finerenone: Insights Based on Phase IIb Data and Simulations to Support Dose Selection for Pivotal Trials in Type 2 Diabetes with Chronic Kidney Disease.
Snelder N, Heinig R, Drenth HJ, Joseph A, Kolkhof P, Lippert J, Garmann D, Ploeger B, Eissing T. Snelder N, et al. Among authors: garmann d. Clin Pharmacokinet. 2020 Mar;59(3):359-370. doi: 10.1007/s40262-019-00820-x. Clin Pharmacokinet. 2020. PMID: 31583611 Free PMC article. Clinical Trial.
NT-proBNP Qualifies as a Surrogate for Clinical End Points in Heart Failure.
Schmitt W, Rühs H, Burghaus R, Diedrich C, Duwal S, Eissing T, Garmann D, Meyer M, Ploeger B, Lippert J. Schmitt W, et al. Among authors: garmann d. Clin Pharmacol Ther. 2021 Aug;110(2):498-507. doi: 10.1002/cpt.2222. Epub 2021 Mar 27. Clin Pharmacol Ther. 2021. PMID: 33630302 Free PMC article.
Finerenone Dose-Exposure-Response for the Primary Kidney Outcome in FIDELIO-DKD Phase III: Population Pharmacokinetic and Time-to-Event Analysis.
van den Berg P, Ruppert M, Mesic E, Snelder N, Seelmann A, Heinig R, Joseph A, Garmann D, Lippert J, Eissing T. van den Berg P, et al. Among authors: garmann d. Clin Pharmacokinet. 2022 Mar;61(3):439-450. doi: 10.1007/s40262-021-01082-2. Epub 2021 Nov 13. Clin Pharmacokinet. 2022. PMID: 34773606 Free PMC article. Clinical Trial.
Finerenone Dose-Exposure-Serum Potassium Response Analysis of FIDELIO-DKD Phase III: The Role of Dosing, Titration, and Inclusion Criteria.
Goulooze SC, Snelder N, Seelmann A, Horvat-Broecker A, Brinker M, Joseph A, Garmann D, Lippert J, Eissing T. Goulooze SC, et al. Among authors: garmann d. Clin Pharmacokinet. 2022 Mar;61(3):451-462. doi: 10.1007/s40262-021-01083-1. Epub 2021 Nov 17. Clin Pharmacokinet. 2022. PMID: 34786651 Free PMC article. Clinical Trial.
34 results